Skip to main content

Drilling for Certainty: The Latest in Fracking Health Studies

Naveena Sadasivam Pro Publica
“The public health sector has been absent from this debate,” said Nadia Steinzor, a researcher on the Oil and Gas Accountability Project at the environmental nonprofit, Earthworks. The science is far from settled. However, waiting for additional science to clarify those uncertainties before adopting more serious safeguards is misguided and dangerous. As a result, a number of researchers and local activists have been pushing for more aggressive oversight immediately.

Edna Pardo - 1921-2014

Graydon Megan Special to the Chicago Tribune
Edna Pardo tireless campaigner on the inequities in Chicago schools, and for fairness in Illinois school finance and the Illinois tax system, and longtime leader of the League of Women Voters of Chicago

The Disgraceful Rejection of Debo Adegbile

Scott Lemieux The American Prospect
Republicans voted against his approval as part of a broader anti-civil rights agenda, but the 7 Democrats who joined them ought to be mortified by their own cowardice.

Another Cold War ?

Tom Hayden The Peace Exchange Bulletin
The new Cold War is upon us, and the American elites have no suggestions except to fight it again.

The Self(ie) Generation

Charles M. Blow New York Times
Millennials - are ‘digital natives’ - the only generation for which - the Internet, mobile technology and social media - are not something they’ve had to adapt to.

The Big Lie about Mayor Bill de Blasio and Charters

Diane Ravitch Diane Ravitch's Blogs
The question before the Mayor is whether he will continue to fund a dual school system–one sector able to choose the students it wants–and the other sector serving all. He is trying to have it both ways, and it doesn’t work. He gave the charter lobby almost everything it wanted, and they still came after him as if he had given them nothing at all.

HIV Gene Therapy Using GM Cells Hailed a Success After Trial

Ian Sample The Guardian
A radical new gene therapy for HIV using genetically modified cells mimics a rare but natural mutation that makes about 1% of the population resistant to the most common strains of HIV. Scientists were cautious not to draw strong conclusions from the small scale trial, which was designed to assess the safety of the therapy, but the early signs have raised their hopes.